David Zaccardelli

David Zaccardelli, listed as chief executive, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Verona Pharma plc, UNITED THERAPEUTICS Corp and Dova Pharmaceuticals Inc. Between 13 May 2016 and 7 October 2025, the trades on record add up to 58 filings.

The open-market side counts 2 purchases for €227k alongside 25 sales for €17.0M. Taken together, the sales exceed the purchases by €16.7M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 17 share grants and 7 option exercises. So far in 2025, the count stands at no purchases and 5 sales.

Most recently, on 8 October 2025, the filings show a transaction in Verona Pharma plc. The latest purchase dates back some time: it was published 2,860 days ago, on 21 December 2018. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.